Clinical outcomes (CO) evaluation of very old (≥80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Updated results of an Italian multicenter retrospective study (cooperative group for DELPHI study)

被引：0
|
作者：
Caffo, O.
Burgio, L. S. [1 ]
Di Lorenzo, G. [2 ]
Ortega, C. [3 ]
Scognamiglio, F. [4 ]
Mattioli, R. [5 ]
Mansueto, G. [6 ]
Facchini, G. [7 ]
Zustovich, F. [8 ]
Maines, F.
机构：
[1] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[2] Univ Naples Federico II, Naples, Italy
[3] Inst Canc Res & Treatment, Candiolo, Italy
[4] Cardarelli Hosp, Naples, Italy
[5] Santa Croce Hosp, Fano, Italy
[6] Civil Hosp, Frosino, Italy
[7] Natl Canc Inst, Naples, Italy
[8] Ist Oncol Veneto IOV, Padua, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2908
引用
收藏
页码：S699 / S699
页数：1
相关论文
共 41 条
  • [21] Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study
    Naoto Kamiya
    Hiroyoshi Suzuki
    Takeshi Ueda
    Naohide Sato
    Hiroomi Nakatsu
    Kazuo Mikami
    Nobuo Sato
    Kazushi Nomura
    Koichiro Akakura
    Tatsuya Okano
    Takemasa Ooki
    Yukio Naya
    Sho Ota
    Motoyuki Masai
    Tomohiko Ichikawa
    International Journal of Clinical Oncology, 2014, 19 : 157 - 164
  • [22] PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY
    Small, Eric J.
    Lee, Ji Youl
    Lopez-Gitlitz, Angela
    Saad, Fred
    Rooney, Brendan
    Hadaschik, Boris A.
    Uemura, Hiroji
    Shu, Youyi
    Yu, Margaret
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E232 - E232
  • [23] Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
    Caffo, Orazio
    De Giorgi, Ugo
    Fratino, Lucia
    Alesini, Daniele
    Zagonel, Vittorina
    Facchini, Gaetano
    Gasparro, Donatello
    Ortega, Cinzia
    Tucci, Marcello
    Verderame, Francesco
    Campadelli, Enrico
    Lo Re, Giovanni
    Procopio, Giuseppe
    Sabbatini, Roberto
    Donini, Maddalena
    Morelli, Franco
    Sartori, Donata
    Zucali, Paolo
    Carrozza, Francesco
    D'Angelo, Alessandro
    Vicario, Giovanni
    Massari, Francesco
    Santini, Daniele
    Sava, Teodoro
    Messina, Caterina
    Fornarini, Giuseppe
    La Torre, Leonardo
    Ricotta, Riccardo
    Aieta, Michele
    Mucciarini, Claudia
    Zustovich, Fable
    Macrini, Sveva
    Burgio, Salvatore Luca
    Santarossa, Sandra
    D'Aniello, Carmine
    Basso, Umberto
    Tarasconi, Sara
    Cortesi, Enrico
    Buttigliero, Consuelo
    Ruatta, Fiorella
    Veccia, Antonello
    Conteduca, Vincenza
    Maines, Francesca
    Galligioni, Enzo
    EUROPEAN UROLOGY, 2015, 68 (01) : 147 - 153
  • [24] Outcomes of post-progression therapies in patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial).
    Caffo, Orazio
    Maruzzo, Marco
    Samuelly, Alessandro
    Facchini, Gaetano
    Zanardi, Elisa
    Nicodemo, Maurizio
    Ermacora, Paola
    Soraru, Mariella
    Galli, Luca
    Cattrini, Carlo
    Borsellino, Nicolo
    Buti, Sebastiano
    Rebuzzi, Sara Elena
    Iacovelli, Roberto
    Rametta, Alessandro
    Calvani, Nicola
    Giordano, Monica
    Farnesi, Azzurra
    Fratino, Lucia
    Basso, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.
    Lutrino, Stefania Eufemia
    Fontanella, Caterina
    Caffo, Orazio
    Massari, Francesco
    Atzori, Francesco
    Maggi, Claudia
    Calvani, Nicola
    Sacco, Cosimo
    Veccia, Antonello
    Modena, Alessandra
    Cugudda, Silvia
    Verzoni, Elena
    Caliolo, Chiara
    Ermacora, Paola
    Maines, Francesca
    Tortora, Giampaolo
    Procopio, Giuseppe
    Ferrara, Pasqualinda
    Fasola, Gianpiero
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [26] Acitivity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
    Caffo, Orazio
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Basso, Umberto
    Alesini, Daniele
    Tucci, Marcello
    Ortega, Cinzia
    Verderame, Francesco
    Procopio, Giuseppe
    Lo Re, Giovanni
    Campadelli, Enrico
    Omarini, Claudia
    Donini, Maddalena
    Morelli, Franco
    Zucali, Paolo A.
    Sartori, Donata
    Conteduca, Vincenza
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [27] Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.
    Caffo, Orazio
    Frantellizzi, Viviana
    Galli, Luca
    Monari, Fabio
    Facchini, Gaetano
    Baldari, Sergio
    Tucci, Marcello
    Alongi, Filippo
    Bortolus, Roberto
    Agostini, Stefania
    Biasco, Elisa
    Fanti, Stefano
    Rossetti, Sabrina
    Pignata, Salvatore
    Zichi, Clizia
    Salgarello, Matteo
    Borsatti, Eugenio
    Cortesi, Enrico
    Sbrana, Andrea
    De Vincentis, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [28] Evaluation of the efficacy and safety of cabazitaxel in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy in daily clinical practice. Results of a Russian multicenter prospective study
    Alekseev, B. Ya
    Shevchuk, I. M.
    ONKOUROLOGIYA, 2020, 16 (01): : 66 - 77
  • [29] Correlation of elevated alkaline phosphatase (ALP) and survival in metastatic castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy: Results of SWSW Uro-oncology Group study from three U. K. centers
    Bahl, A. K.
    Bertelli, G.
    Lewis, P. D.
    Jenkins, P.
    Aziz, A.
    Davies, P. J.
    Persad, R.
    Smith, C. G.
    Hurley, K.
    Mason, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [30] Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.
    Veccia, Antonello
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Alesini, Daniele
    Basso, Umberto
    Tucci, Marcello
    Ortega, Cinzia
    Scagliarini, Sarah
    Verderame, Francesco
    Lo Re, Giovanni
    Procopio, Giuseppe
    Sabbatini, Roberto
    Campadelli, Enrico
    Zucali, Paolo Andrea
    Morelli, Franco
    Sartori, Donata
    Conteduca, Vincenza
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345